PRLD has 36-month beta value of 1.48. Analysts have mixed views on the stock, with 1 analysts rating it as a “buy,” 2 as “overweight,” 0 as “hold,” and 1 as “sell.”
The public float for PRLD is 21.87M, and currently, short sellers hold a 13.98% ratio of that float. The average trading volume of PRLD on December 11, 2024 was 377.02K shares.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
PRLD) stock’s latest price update
Prelude Therapeutics Inc (NASDAQ: PRLD) has experienced a decline in its stock price by -6.18 compared to its previous closing price of 0.97. However, the company has seen a fall of -4.20% in its stock price over the last five trading days. globenewswire.com reported 2024-12-11 that • PRT2527 demonstrated activity across a range of relapsed/refractory lymphoid malignancies, including patients who received prior CAR-T therapy
PRLD’s Market Performance
PRLD’s stock has fallen by -4.20% in the past week, with a monthly drop of -23.52% and a quarterly drop of -81.16%. The volatility ratio for the week is 10.42% while the volatility levels for the last 30 days are 7.38% for Prelude Therapeutics Inc The simple moving average for the past 20 days is -7.77% for PRLD’s stock, with a -74.81% simple moving average for the past 200 days.
Analysts’ Opinion of PRLD
Many brokerage firms have already submitted their reports for PRLD stocks, with H.C. Wainwright repeating the rating for PRLD by listing it as a “Buy.” The predicted price for PRLD in the upcoming period, according to H.C. Wainwright is $5 based on the research report published on September 19, 2024 of the current year 2024.
Barclays, on the other hand, stated in their research note that they expect to see PRLD reach a price target of $3. The rating they have provided for PRLD stocks is “Underweight” according to the report published on June 20th, 2024.
JMP Securities gave a rating of “Mkt Outperform” to PRLD, setting the target price at $7 in the report published on March 13th of the current year.
PRLD Trading at -33.70% from the 50-Day Moving Average
After a stumble in the market that brought PRLD to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -86.62% of loss for the given period.
Volatility was left at 7.38%, however, over the last 30 days, the volatility rate increased by 10.42%, as shares sank -17.39% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -53.20% lower at present.
During the last 5 trading sessions, PRLD remain unchanged, which changed the moving average for the period of 200-days by -77.33% in comparison to the 20-day moving average, which settled at $0.9888. In addition, Prelude Therapeutics Inc saw -78.69% in overturn over a single year, with a tendency to cut further losses.
Stock Fundamentals for PRLD
Current profitability levels for the company are sitting at:
- -22.3 for the present operating margin
- 0.81 for the gross margin
The net margin for Prelude Therapeutics Inc stands at -20.47. The total capital return value is set at -0.82. Equity return is now at value -66.64, with -57.72 for asset returns.
Currently, EBITDA for the company is -131.11 million with net debt to EBITDA at -0.05. When we switch over and look at the enterprise to sales, we see a ratio of 8.97. The liquidity ratio also appears to be rather interesting for investors as it stands at 7.04.
Conclusion
To put it simply, Prelude Therapeutics Inc (PRLD) has had a bad performance in recent times. Analysts have a mixed opinion on the stock, with some rating it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
